Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is designed for descriptive pharmacokinetic characterization of ketamine and
norketamine in serum, urine and feces after oral single dose administration of a new
developed prolonged release tablet formulation containing 10, 20, 40 and 80 mg ketamine under
fasting conditions and for descriptive pharmacokinetic characterization of ketamine and
norketamine in serum, urine and feces after intravenous single dose administration of 5 mg
ketamine solution for infusion within 30 min